Cell Cycle
Volume 17, 2018 - Issue 5
Reports
Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells
Claire LevrierAustralian Prostate Cancer Research Centre−Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia;Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia
http://orcid.org/0000-0003-0439-0176View further author information
http://orcid.org/0000-0003-0439-0176View further author information, Anja RockstrohAustralian Prostate Cancer Research Centre−Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australiahttp://orcid.org/0000-0002-2700-375XView further author information
http://orcid.org/0000-0002-2700-375XView further author information, Brian GabrielliThe University of Queensland Diamantina Institute; Translational Research Institute; Brisbane, QLD, Australiahttp://orcid.org/0000-0003-3933-1651View further author information
http://orcid.org/0000-0003-3933-1651View further author information, Maria KavallarisTumour Biology and Targeting Program, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, Sydney, NSW, Australia;ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and Australian Centre for NanoMedicine, UNSW Australia, Sydney, NSW, Australiahttp://orcid.org/0000-0003-2309-898XView further author information
http://orcid.org/0000-0003-2309-898XView further author information, Melanie LehmanAustralian Prostate Cancer Research Centre−Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia;Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canadahttp://orcid.org/0000-0003-0500-2411View further author information
http://orcid.org/0000-0003-0500-2411View further author information, Rohan A. DavisAustralian Prostate Cancer Research Centre−Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia;Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australiahttp://orcid.org/0000-0003-4291-7573View further author information
http://orcid.org/0000-0003-4291-7573View further author information, Martin C. SadowskiAustralian Prostate Cancer Research Centre−Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australiahttp://orcid.org/0000-0002-5267-1442View further author information
http://orcid.org/0000-0002-5267-1442View further author information & Colleen C. NelsonAustralian Prostate Cancer Research Centre−Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, AustraliaCorrespondence[email protected]
http://orcid.org/0000-0001-6410-4843View further author information
http://orcid.org/0000-0001-6410-4843View further author information show all